<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15108">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02110108</url>
  </required_header>
  <id_info>
    <org_study_id>CYN14-REV-REJUV-NS</org_study_id>
    <nct_id>NCT02110108</nct_id>
  </id_info>
  <brief_title>Study for the RevLite Laser System for Facial Solar Lentigines</brief_title>
  <official_title>Study for the RevLite Laser System for Facial Solar Lentigines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of the Revlite Laser System for
      treatment of facial solar lentigines
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Photographic evaluation using the Global Aesthetic Improvement Scale</measure>
    <time_frame>1 month post last treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Photos taken at baseline will be compared to photos taken 1 month post last treatment to assess level of improvement using the Global Aesthetic Improvement Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction Questionnaire</measure>
    <time_frame>1 month post last treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Facial Solar Lentigines</condition>
  <arm_group>
    <arm_group_label>Revlite Laser System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Revlite Laser System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Revlite Laser System</intervention_name>
    <description>Revlite Laser System for the Treatment of Facial Solar Lentigines</description>
    <arm_group_label>Revlite Laser System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is a healthy male or female between 18 and 60 years old.

          2. Is Fitzpatrick Skin types I-III

          3. Is willing to consent to participate in the study.

          4. Is willing to comply with all requirements of the study including being photographed,
             following post treatment care and attending all treatment and follow up visits.

          5. Has clinically determined mild to severe facial mottled pigmentation (solar
             lentigines) on the face.

        Exclusion Criteria:

          1. Is female and pregnant, has been pregnant within the last 3 months, is currently
             breast feeding or planning a pregnancy during the study period.

          2. Is hypersensitive to light exposure OR takes photo sensitized medication.

          3. Has active or localized systemic infections.

          4. Has a coagulation disorder or is currently using anti-coagulation medication
             (including but not limited to the heavy use of aspirin {greater than 81 mg per day}).

          5. Has any condition which, in the investigator's opinion, would make it unsafe for the
             subject to participate in this research study.

          6. Is currently enrolled in an investigational drug or device trial, or has received an
             investigational drug or been treated with an investigational device within 3 months
             prior to entering this study.

          7. Has used Accutane within 6 months prior to enrollment.

          8. Has the need to be exposed to artificial tanning devices or excessive sunlight during
             the trial.

          9. Has had prior treatment with parenteral gold therapy (gold sodium thiomalate).

         10. Has a history of keloids.

         11. Has evidence of compromised wound healing.

         12. Has a history of basal cell carcinoma, squamous cell carcinoma or melanoma.

         13. Has a history of immunosuppression/immune deficiency disorders (including HIV
             infection or AIDS) or use of immunosuppressive medications or has an autoimmune
             disorder.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Krantz</last_name>
    <role>Study Director</role>
    <affiliation>Cynosure, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sadick Research Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>April 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Facies</mesh_term>
    <mesh_term>Lentigo</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
